Marksans Pharma jumps on getting USFDA’s final nod for Benzonatate Capsules
Marksans Pharma is currently trading at Rs. 167.80, up by 10.65 points or 6.78% from its previous closing of Rs. 157.15 on the BSE.
The scrip opened at Rs. 164.20 and has touched a high and low of Rs. 171.25 and Rs. 160.35 respectively. So far 58424 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 270.60 on 11-Jun-2025 and a 52 week low of Rs. 156.00 on 30-Mar-2026.
Last one week high and low of the scrip stood at Rs. 171.25 and Rs. 156.00 respectively. The current market cap of the company is Rs. 7649.40 crore.
The promoters holding in the company stood at 43.87%, while Institutions and Non-Institutions held 14.03% and 42.09% respectively.
Marksans Pharma has received the final approval for Abbreviated New Drug Application (ANDA) from United States Food and Drug Administration (USFDA) for Benzonatate Capsules USP, 100 mg & 200 mg (Rx).
This product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Tessalon Capsules, 100 mg and 200 mg, of Pfizer Inc. Benzonatate is a non-narcotic antitussive that numbs stretch receptors in the respiratory tract, reducing the cough reflex and relieving persistent cough, bronchitis, pneumonia or other lung infections.
